https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/research

The Latest

couple on the boardwalk surrounded by seagulls

This Week in HIV Research: When STIs Flock Together

July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.

man getting vaccine

Large Scale HIV Vaccine Trial Announced, But PrEP May Challenge Enrollment

Will potential study participants choose a vaccine trial over getting access to PrEP?

Close up of doctor examining of test sample under the microscope

Researchers Discuss Ethics and Privacy Concerns About the Growing Field of HIV Adherence Monitoring

"A lot of patients want to know, 'Who else is going to see this data?'" said Peter Chai of Fenway Health in Boston.

illustration of person on cliff with arms raised as sun rises/sets

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid Img

Staying on PrEP is Significantly Different for PrEP Users With Commercial Insurance Versus Medicaid

Young adults, blacks, cisgender women, and people in rural areas, as well as people on Medicaid, were less likely to persist on PrEP.

CROI 2019: What News to Expect in HIV Science and Policy

TheBodyPro is covering all the latest in HIV science at the biggest annual gathering of HIV researchers in the U.S. Here's a preview of what's to come.

This Week in HIV Research: Rethinking PrEP Guidelines

Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.